Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

Jonathan Wall, Stephen Kennel, Alan C. Stuckey, Misty J. Long, David W. Townsend, Gary T. Smith, Karen J. Wells, Yitong Fu, Michael G. Stabin, Deborah T. Weiss, Alan Solomon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Care of patients with AL amyloidosis currently is limited by the lack of objective means to document disease extent, as well as therapeutic options that expedite removal of pathologic deposits. To address these issues, we have initiated a Phase I Exploratory IND study to determine the biodistribution of the fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124. Patients were infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody and imaged by PET/CT scan 48 and 120 hours later. Among 9 of 18 subjects, there was striking uptake of the reagent in liver, lymph nodes, bone marrow, intestine, or, unexpectedly, spleen (but not kidneys or heart). Generally, positive or negative results correlated with those obtained immunohistochemically using diagnostic tissue biopsy specimens. Based on these findings, we posit that 124I-mAb m11-1F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the antibody. This trial was registered at www.clinicaltrials.gov as NCT00807872.

Original languageEnglish (US)
Pages (from-to)2241-2244
Number of pages4
JournalBlood
Volume116
Issue number13
DOIs
StatePublished - Sep 30 2010

Fingerprint

Radioimmunodetection
Amyloid Plaques
Amyloidosis
Amyloid
Deposits
Passive Immunization
Computerized tomography
Antibodies
Biopsy
Liver
Intestines
Patient Care
Bone
Spleen
Immunoglobulin G
Lymph Nodes
Bone Marrow
Tissue
Kidney
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. / Wall, Jonathan; Kennel, Stephen; Stuckey, Alan C.; Long, Misty J.; Townsend, David W.; Smith, Gary T.; Wells, Karen J.; Fu, Yitong; Stabin, Michael G.; Weiss, Deborah T.; Solomon, Alan.

In: Blood, Vol. 116, No. 13, 30.09.2010, p. 2241-2244.

Research output: Contribution to journalArticle

Wall, J, Kennel, S, Stuckey, AC, Long, MJ, Townsend, DW, Smith, GT, Wells, KJ, Fu, Y, Stabin, MG, Weiss, DT & Solomon, A 2010, 'Radioimmunodetection of amyloid deposits in patients with AL amyloidosis', Blood, vol. 116, no. 13, pp. 2241-2244. https://doi.org/10.1182/blood-2010-03-273797
Wall, Jonathan ; Kennel, Stephen ; Stuckey, Alan C. ; Long, Misty J. ; Townsend, David W. ; Smith, Gary T. ; Wells, Karen J. ; Fu, Yitong ; Stabin, Michael G. ; Weiss, Deborah T. ; Solomon, Alan. / Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. In: Blood. 2010 ; Vol. 116, No. 13. pp. 2241-2244.
@article{10a59627c5554b5083b40a53a5c2034a,
title = "Radioimmunodetection of amyloid deposits in patients with AL amyloidosis",
abstract = "Care of patients with AL amyloidosis currently is limited by the lack of objective means to document disease extent, as well as therapeutic options that expedite removal of pathologic deposits. To address these issues, we have initiated a Phase I Exploratory IND study to determine the biodistribution of the fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124. Patients were infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody and imaged by PET/CT scan 48 and 120 hours later. Among 9 of 18 subjects, there was striking uptake of the reagent in liver, lymph nodes, bone marrow, intestine, or, unexpectedly, spleen (but not kidneys or heart). Generally, positive or negative results correlated with those obtained immunohistochemically using diagnostic tissue biopsy specimens. Based on these findings, we posit that 124I-mAb m11-1F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the antibody. This trial was registered at www.clinicaltrials.gov as NCT00807872.",
author = "Jonathan Wall and Stephen Kennel and Stuckey, {Alan C.} and Long, {Misty J.} and Townsend, {David W.} and Smith, {Gary T.} and Wells, {Karen J.} and Yitong Fu and Stabin, {Michael G.} and Weiss, {Deborah T.} and Alan Solomon",
year = "2010",
month = "9",
day = "30",
doi = "10.1182/blood-2010-03-273797",
language = "English (US)",
volume = "116",
pages = "2241--2244",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Radioimmunodetection of amyloid deposits in patients with AL amyloidosis

AU - Wall, Jonathan

AU - Kennel, Stephen

AU - Stuckey, Alan C.

AU - Long, Misty J.

AU - Townsend, David W.

AU - Smith, Gary T.

AU - Wells, Karen J.

AU - Fu, Yitong

AU - Stabin, Michael G.

AU - Weiss, Deborah T.

AU - Solomon, Alan

PY - 2010/9/30

Y1 - 2010/9/30

N2 - Care of patients with AL amyloidosis currently is limited by the lack of objective means to document disease extent, as well as therapeutic options that expedite removal of pathologic deposits. To address these issues, we have initiated a Phase I Exploratory IND study to determine the biodistribution of the fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124. Patients were infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody and imaged by PET/CT scan 48 and 120 hours later. Among 9 of 18 subjects, there was striking uptake of the reagent in liver, lymph nodes, bone marrow, intestine, or, unexpectedly, spleen (but not kidneys or heart). Generally, positive or negative results correlated with those obtained immunohistochemically using diagnostic tissue biopsy specimens. Based on these findings, we posit that 124I-mAb m11-1F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the antibody. This trial was registered at www.clinicaltrials.gov as NCT00807872.

AB - Care of patients with AL amyloidosis currently is limited by the lack of objective means to document disease extent, as well as therapeutic options that expedite removal of pathologic deposits. To address these issues, we have initiated a Phase I Exploratory IND study to determine the biodistribution of the fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124. Patients were infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody and imaged by PET/CT scan 48 and 120 hours later. Among 9 of 18 subjects, there was striking uptake of the reagent in liver, lymph nodes, bone marrow, intestine, or, unexpectedly, spleen (but not kidneys or heart). Generally, positive or negative results correlated with those obtained immunohistochemically using diagnostic tissue biopsy specimens. Based on these findings, we posit that 124I-mAb m11-1F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the antibody. This trial was registered at www.clinicaltrials.gov as NCT00807872.

UR - http://www.scopus.com/inward/record.url?scp=77957707133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957707133&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-03-273797

DO - 10.1182/blood-2010-03-273797

M3 - Article

C2 - 20522711

AN - SCOPUS:77957707133

VL - 116

SP - 2241

EP - 2244

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -